Barclays PLC Has $303,000 Stock Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Barclays PLC lifted its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 79.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,174 shares of the company’s stock after buying an additional 47,059 shares during the period. Barclays PLC owned about 0.08% of Nautilus Biotechnology worth $303,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of Nautilus Biotechnology in the 3rd quarter valued at about $50,000. The Manufacturers Life Insurance Company bought a new stake in shares of Nautilus Biotechnology in the 3rd quarter valued at about $67,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after purchasing an additional 9,404 shares during the period. MetLife Investment Management LLC bought a new stake in shares of Nautilus Biotechnology in the 3rd quarter valued at about $87,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Nautilus Biotechnology by 11.2% in the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after purchasing an additional 14,100 shares during the period. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group cut shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their target price for the company from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Stock Down 1.2 %

Nautilus Biotechnology stock opened at $1.67 on Monday. The stock has a market cap of $209.69 million, a P/E ratio of -2.98 and a beta of 1.14. Nautilus Biotechnology, Inc. has a twelve month low of $1.61 and a twelve month high of $3.25. The company’s 50-day moving average price is $2.19 and its two-hundred day moving average price is $2.46.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. Equities analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.